Obesity, Inflammation, and Prostate Cancer

Area of Science:

• Oncology
• Immunology
• Metabolic Syndrome

Background:

• Rising global obesity rates contribute to increased incidence of obesity-induced diseases, including cardiovascular disease and malignancies.
• Epidemiological data indicate a correlation between obesity and advanced prostate cancer, with obese men experiencing poorer prognoses.
• Obesity promotes systemic inflammation through various mechanisms, impacting cancer progression.

Purpose of the Study:

• To explore the intricate relationship between obesity, systemic inflammation, and prostate cancer progression.
• To investigate how obesity alters the tumor microenvironment and immune cell profiles in prostate cancer.
• To identify potential therapeutic targets for prostate cancer in the context of obesity.

Main Methods:

• Review of epidemiological studies linking obesity and prostate cancer prognosis.
• Analysis of mechanisms by which obesity-induced inflammation influences prostate cancer.
• Examination of the role of immune cells (e.g., myeloid-derived suppressor cells, macrophages, neutrophils) in obesity-associated prostate cancer.

Main Results:

• Obesity is associated with advanced prostate cancer and worse patient outcomes.
• High-fat diets and obesity promote prostate cancer progression via inflammatory cytokines and chemokines secreted by adipose tissue.
• Obesity alters the local immune cell landscape within the prostate tumor microenvironment, potentially promoting cancer growth.

Conclusions:

• Systemic and local inflammation driven by obesity play a significant role in prostate cancer progression.
• Immune cells such as myeloid-derived suppressor cells, macrophages, neutrophils, B cells, and complement factors may contribute to prostate cancer in obese individuals.
• Interventions targeting inflammation and lifestyle modifications represent promising therapeutic avenues for managing prostate cancer in obese patients.